Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRT3645 |
Synonyms | |
Therapy Description |
PRT3645 is a brain-penetrant inhibitor of CDK4 and CDK6, which potentially leads to decreased tumor cell proliferation and tumor growth (Cancer Res (2022) 82 (12_Supplement): 2300). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRT3645 | PRT 3645|PRT-3645 | CDK4/6 Inhibitor 14 | PRT3645 is a brain-penetrant inhibitor of CDK4 and CDK6, which potentially leads to decreased tumor cell proliferation and tumor growth (Cancer Res (2022) 82 (12_Supplement): 2300). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | 1 |